Free Trial
→ My next big call (under $1) (From Crypto 101 Media) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
$1.90
-4.5%		$2.13
$1.79
▼
$5.18
$39.98M0.33369,668 shs155,453 shs
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
$3.10
$3.10
$2.50
▼
$13.00
$10.58M2.352,472 shsN/A
RYTHM, Inc. stock logo
RYM
RYTHM
$18.21
-2.8%		$21.96
$14.00
▼
$53.65
$39.71M9.4614,909 shs8,768 shs
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$3.96
-0.9%		$4.90
$3.53
▼
$9.12
$39.35M1.06137,764 shs42,203 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
-1.49%-3.86%-10.36%-18.11%-33.22%
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.00%0.00%0.00%0.00%0.00%
RYTHM, Inc. stock logo
RYM
RYTHM
-0.94%-5.04%-12.41%-18.43%-58.19%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-0.99%-17.56%-17.56%-17.39%-38.59%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
$1.90
-4.5%		$2.13
$1.79
▼
$5.18
$39.98M0.33369,668 shs155,453 shs
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
$3.10
$3.10
$2.50
▼
$13.00
$10.58M2.352,472 shsN/A
RYTHM, Inc. stock logo
RYM
RYTHM
$18.21
-2.8%		$21.96
$14.00
▼
$53.65
$39.71M9.4614,909 shs8,768 shs
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$3.96
-0.9%		$4.90
$3.53
▼
$9.12
$39.35M1.06137,764 shs42,203 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
-1.49%-3.86%-10.36%-18.11%-33.22%
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.00%0.00%0.00%0.00%0.00%
RYTHM, Inc. stock logo
RYM
RYTHM
-0.94%-5.04%-12.41%-18.43%-58.19%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-0.99%-17.56%-17.56%-17.39%-38.59%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
2.00
Hold$6.00215.79% Upside
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.00
N/AN/AN/A
RYTHM, Inc. stock logo
RYM
RYTHM
1.00
SellN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
2.33
Hold$33.00734.39% Upside

Current Analyst Ratings Breakdown

Latest PHXM, GRCE, RYM, and SCYX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2026
RYTHM, Inc. stock logo
RYM
RYTHM
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
8/13/2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$24.00 ➝ $33.00
8/3/2026
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold
7/31/2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
Brookline Capital Markets logo
Brookline Capital Markets
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
7/24/2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
7/17/2026
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/AN/AN/AN/A$3.99 per shareN/A
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
N/AN/AN/AN/A$7.98 per shareN/A
RYTHM, Inc. stock logo
RYM
RYTHM
$17.28M2.30N/AN/A$6.06 per share3.00
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$20.60M1.91N/AN/A$9.07 per share0.44
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
-$7.79M-$1.18N/AN/AN/AN/A-36.11%-34.39%11/12/2026 (Estimated)
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
-$240KN/AN/AN/AN/AN/AN/AN/AN/A
RYTHM, Inc. stock logo
RYM
RYTHM
-$33.26M-$10.53N/AN/AN/A-6.20%-12.57%-2.60%N/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$8.61M-$2.09N/AN/AN/AN/A-44.15%-32.61%11/4/2026 (Estimated)

Latest PHXM, GRCE, RYM, and SCYX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$0.72N/AN/AN/A$0.13 millionN/A
8/14/2026Q1 2027
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
-$0.1293-$0.91-$0.7807-$0.91$0.40 millionN/A
8/10/2026Q2 2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$0.5067$0.63+$1.1367$0.63$0.08 million$0.24 million
8/4/2026Q2 2026
RYTHM, Inc. stock logo
RYM
RYTHM
N/A$0.09N/A$0.09N/A$23.02 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/AN/AN/AN/AN/A
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
N/AN/AN/AN/AN/A
RYTHM, Inc. stock logo
RYM
RYTHM
N/AN/AN/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/A
11.47
11.47
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.23
1.78
N/A
RYTHM, Inc. stock logo
RYM
RYTHM
N/A
0.59
0.56
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/A
9.65
9.65

Institutional Ownership

CompanyInstitutional Ownership
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
6.08%
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.40%
RYTHM, Inc. stock logo
RYM
RYTHM
5.98%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
54.37%

Insider Ownership

CompanyInsider Ownership
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
10.84%
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
1.94%
RYTHM, Inc. stock logo
RYM
RYTHM
3.48%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
4.09%
CompanyEmployeesShares OutstandingFree FloatOptionable
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
521.04 million18.76 millionN/A
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
493.41 million3.35 millionNo Data
RYTHM, Inc. stock logo
RYM
RYTHM
1412.18 million2.10 millionN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
299.95 million9.54 millionOptionable

Recent News About These Companies

SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease
October 7, 2026  |  marketscreener.comM
SCYNEXIS (NASDAQ:SCYX) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell?
October 7, 2026  |  defenseworld.netD
SCYNEXIS (NASDAQ:SCYX) Shares Cross Above Fifty Day Moving Average - What's Next?
October 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31094633
SCYNEXIS (NASDAQ:SCYX) Stock Price Crosses Above Fifty Day Moving Average - Time to Sell?
October 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-scynexis-nasdaq-scyx-stock-price-crosses-above-fifty-day-moving-average-time-to-sell-2026-10-07/
SCYNEXIS Reports Favorable Phase 1 Results For ADPKD Drug
October 6, 2026  |  rttnews.comhttps://www.rttnews.com/3696850/scynexis-reports-favorable-phase-1-results-for-adpkd-drug.aspx
SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease ...
October 6, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/scynexis-announces-phase-1-study-results-for-scy-770-a-novel-highly-selective-oral-direct-ampk-activator-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd-1036600549
SCYNEXIS Announces Positive Phase 1 Results for SCY-770 in ADPKD, Supports Planned Phase 2 Study in Q4 2026
October 6, 2026  |  quiverquant.comQ
SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375347/0/en/scynexis-announces-phase-1-study-results-for-scy-770-a-novel-highly-selective-oral-direct-ampk-activator-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd.html
SCYNEXIS Secures BARDA Funding for Antifungal Pipeline
September 30, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SCYX/pressreleases/4866303/scynexis-secures-barda-funding-for-antifungal-pipeline/
SCYNEXIS Secures BARDA Funding for Antifungal Pipeline
September 30, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SCYX/pressreleases/4866303/scynexis-secures-barda-funding-for-antifungal-pipeline/
Scynexis stock surges on $214M BARDA contract for SCY-247
September 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/scynexis-stock-surges-214m-barda-135830821.html
Scynexis Shares Rise 13.9% After BARDA Awards SCY-247 Development Contract
September 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/scynexis-shares-rise-13-9-121017917.html
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
September 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/28/3369788/0/en/scynexis-awarded-barda-contract-providing-up-to-214-million-in-non-dilutive-funding-for-the-development-of-scy-247.html
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
September 22, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/scynexis-appoints-seasoned-industry-veteran-steven-k-burke-m-d-to-its-board-of-directors-1036563490
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D.
September 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/22/3366246/0/en/scynexis-appoints-seasoned-industry-veteran-steven-k-burke-m-d-to-its-board-of-directors.html
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
September 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/15/3362033/0/en/scynexis-appoints-todd-minga-m-d-as-senior-vice-president-research-development.html
SCYNEXIS Names Sanjay Subramanian as CFO
September 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/scynexis-names-sanjay-subramanian-cfo-125711695.html
Scynexis Names Sanjay Subramanian CFO
September 10, 2026  |  rttnews.comhttps://www.rttnews.com/3690011/scynexis-names-sanjay-subramanian-cfo.aspx
SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer
September 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/10/3359427/0/en/scynexis-announces-appointment-of-sanjay-subramanian-as-chief-financial-officer.html
SCYNEXIS to Participate in Upcoming Investor Conferences
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354140/0/en/scynexis-to-participate-in-upcoming-investor-conferences.html
SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
August 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/25/3351035/0/en/scynexis-announces-inducement-award-under-nasdaq-listing-rule-5635-c-4.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Grace Therapeutics stock logo

Grace Therapeutics NASDAQ:GRCE

$1.90 -0.09 (-4.52%)
As of 03:21 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.

PHAXIAM Therapeutics stock logo

PHAXIAM Therapeutics NASDAQ:PHXM

$3.10 0.00 (0.00%)
As of 10/13/2026

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

RYTHM stock logo

RYTHM NASDAQ:RYM

$18.21 -0.52 (-2.80%)
As of 03:21 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Agrify Corporation develops precision hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. The company offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. It also provides associated services comprising consulting, engineering, and construction. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Billerica, Massachusetts.

SCYNEXIS stock logo

SCYNEXIS NASDAQ:SCYX

$3.96 -0.04 (-0.88%)
As of 03:12 PM Eastern
This is a fair market value price provided by Massive. Learn more.

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas